GlassScriptPhysician profile
Matthew Frederick Cohen
NPI 1437219748
$3,974.20
in general payments reported to CMS, 2019-2025
29 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $163 · 2021: $365 · 2022: $783 · 2023: $730 · 2024: $872 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,959.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $771.23 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $718.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $385.63 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $316.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $222.72 | 2022-2023 | |
| Pfizer INC. | $175.39 | 2019-2025 | |
| Glaxosmithkline, LLC. | $163.56 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.68 | 2023-2025 | Jardiance |
| Intercept Pharmaceuticals, INC. | $146.05 | 2019-2023 | Ocaliva |
| Amarin Pharma, INC. | $135.31 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.67 | 2024-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $94.20 | 2022-2024 | Xarelto |
| Exact Sciences Corporation | $73.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $73.39 | 2022 | |
| Astellas Pharma US INC | $70.60 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $70.13 | 2019 | |
| Merck Sharp & Dohme LLC | $44.07 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.26 | 2024 | |
| Amgen INC. | $30.29 | 2022 | |
| Abbott Laboratories | $25.51 | 2021 | |
| Eisai INC. | $24.06 | 2024 | |
| Dexcom, INC. | $22.43 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $19.74 | 2020 | |
| Allergan, INC. | $18.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.34 | 2024 | Camzyos |
| Sunovion Pharmaceuticals INC. | $15.27 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.28 | 2019 | |
| Concordia Pharmaceuticals INC. | $12.22 | 2019 | |
| Dynavax Technologies Corporation | $6.64 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.